

Contents

Preface — V

Foreword — VII

Chapter 1

Introduction to smart pharma: foundation of AI and big data — 1

- 1.1 Introduction — 1
- 1.2 Big data in the pharmaceutical landscape — 3
- 1.3 Integration of big data and AI in pharmaceutical research — 6
- 1.4 Role of stakeholders — 7
- 1.5 Challenges and conquering strategies in smart pharma: foundation of AI and big data — 10
- 1.6 Conclusion — 11
- Reference — 12

Chapter 2

Emerging technology in pharma and the role of AI and blockchain — 19

- 2.1 Introduction — 19
- 2.2 Role of blockchain in the pharmaceutical industry — 22
- 2.3 Convergence of AI and blockchain in the pharmaceutical industry — 24
- 2.4 Regulatory considerations of AI in pharma — 27
- 2.5 Challenges of blockchain in pharma — 29
- 2.6 Conclusion — 31
- Reference — 32

Chapter 3

Partnership and collaboration in the pharmaceutical industry — 37

- 3.1 Introduction — 37
- 3.2 Types of partnerships involved in pharmaceutical industry — 39
 - 3.2.1 Inter-firm collaborations — 40
 - 3.2.2 Public-private partnerships — 41
 - 3.2.3 Academic-industry partnership — 41
 - 3.2.4 Collaboration with start-up — 42
 - 3.2.5 Collaborations with R&D industries — 43
- 3.3 Motivation for alliances in the pharma sector — 43
- 3.4 Challenges in pharmaceutical collaboration — 45
- 3.5 AI-assisted pharma collaborations — 47
- 3.6 Conclusion — 48
- Reference — 49

Chapter 4

Education and training in smart pharma — 55

- 4.1 Introduction — **55**
- 4.2 Key technologies in smart pharma — **57**
 - 4.2.1 Big data in smart pharma — **57**
 - 4.2.2 Blockchain in smart pharma — **58**
 - 4.2.3 ML in smart pharma — **59**
 - 4.2.4 Deep learning in smart pharma — **60**
 - 4.2.5 Internet of things in smart pharma — **60**
- 4.3 Innovative training methods in smart pharma — **61**
- 4.4 Industry-academic collaboration — **63**
- 4.5 Challenges faced by smart pharma — **65**
- 4.6 Conclusion — **68**
 - Reference — **69**

Chapter 5

Drug manufacturing and quality control with artificial intelligence — 77

- 5.1 Introduction — **77**
- 5.2 AI application in pharmaceutical manufacturing — **79**
- 5.3 Application of AI in quality control of pharmaceuticals — **82**
- 5.4 Data management and security — **84**
- 5.5 Regulatory compliance in AI-based manufacturing — **87**
- 5.6 Conclusion — **89**
 - Reference — **90**

Chapter 6

Drug development and clinical trial via artificial intelligence — 97

- 6.1 Introduction — **97**
- 6.2 Computational drug discovery techniques — **100**
- 6.3 AI-powered target determination and validation for clinical trials and drug development — **103**
- 6.4 Machine learning algorithm in pharmacokinetics and pharmacodynamics — **105**
- 6.5 Ethical challenges AI-enabled for clinical trials — **108**
- 6.6 Conclusion — **111**
 - References — **112**

Chapter 7

AI-driven clinical decision support systems for pharma executives — 121

- 7.1 Introduction — **121**
- 7.2 Key components of AI-driven decision support system — **124**
- 7.3 Integrating AI into pharma executive decision-making — **127**

- 7.4 Regulatory compliance and ethical consideration — **130**
- 7.5 Future trends of AI in the pharmaceutical industry — **132**
- 7.6 Conclusion — **134**
- Reference — **135**

Chapter 8

AI-based pharmacovigilance and drug safety — 143

- 8.1 Introduction — **143**
- 8.2 Foundation of AI in pharmacovigilance — **146**
- 8.3 Challenges and opportunities of AI in pharmacovigilance and drug safety — **149**
- 8.4 Collaboration and partnership for drug safety — **151**
- 8.5 Regulatory aspects of AI in pharmacovigilance and drug safety — **153**
- 8.6 Conclusion — **156**
- Reference — **156**

Chapter 9

Intellectual property and data privacy in the pharmaceutical sector — 163

- 9.1 Introduction — **163**
- 9.2 Intellectual property rights landscape — **165**
 - 9.2.1 The patent — **165**
 - 9.2.2 The copyright — **166**
 - 9.2.3 The trademark — **167**
 - 9.2.4 The trade secret — **168**
- 9.3 Data privacy in pharmaceutical industry — **169**
 - 9.3.1 Authentication — **170**
 - 9.3.2 Encryption — **170**
 - 9.3.3 Data masking — **171**
 - 9.3.4 Access control — **171**
- 9.4 Emerging technology and intellectual property — **173**
- 9.5 Challenges of data privacy in the pharmaceutical industry — **174**
- 9.6 Conclusion — **177**
- Reference — **178**

Chapter 10

Regulatory affairs and compliance in the pharmaceutical sector — 183

- 10.1 Introduction — **183**
- 10.2 Regulatory bodies and framework — **185**
 - 10.2.1 Food and Drug Administration (FDA) — **185**
 - 10.2.2 European Medicine Agency (EMA) — **187**
 - 10.2.3 Other regulatory bodies — **187**
- 10.3 AI-based compliance strategies in the pharmaceutical industry — **188**

10.3.1	Good Manufacturing Practices (GMP) —	188
10.3.2	Good Clinical Practices (GCP) —	190
10.3.3	Good Laboratory Practices (GLP) —	191
10.4	Applications of AI in regulatory affairs —	192
10.5	Conclusion —	194
	Reference —	195

Chapter 11

AI and big data in post-marketing surveillance — 201

11.1	Introduction —	201
11.2	Role of machine learning in post-marketing surveillance —	204
11.3	Role of big data analytics in post-marketing surveillance —	206
11.4	Challenges of AI in post-marketing surveillance —	209
11.5	Conclusion —	212
	Reference —	213

Chapter 12

Challenges and ethical considerations — 219

12.1	Introduction —	219
12.2	Challenges in implementing AI in healthcare —	221
12.3	Ethical consideration in AI-driven healthcare —	224
12.4	Impact on healthcare professionals —	227
12.5	Patient perspective and engagement —	228
12.6	Conclusion —	230
	Reference —	230

Chapter 13

Future trends and innovations of AI in healthcare — 237

13.1	Introduction —	237
13.2	Future trends and innovation of AI in drug discovery —	239
13.3	Future trends and innovations of AI in drug manufacturing —	242
13.4	Future trends and innovations of AI in healthcare —	245
13.5	Conclusion —	247
	Reference —	248

Index — 253